2 hot growth stocks with spectacular potential

Royston Wild runs the rule over two hot earnings stars.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Accommodation play Dalata Hotel Group‘s (LSE: DAL) focus on the thriving Irish tourism sector establishes it as one of the hottest, and potentially most undervalued, hotel operators on the London stock market in my opinion.

Dalata — which controls the Clayton Hotels and Maldron Hotels brands — sources almost two-thirds of total profits from Dublin alone, but is embarking on exciting expansion elsewhere to keep the bottom line booming.

Chairman John Hennessy commented this month that “following another year of significant growth in the size of our portfolio and earnings in 2016, trading performance in the first four months of 2017 has been marginally ahead of expectations.”

And Dalata keeps on investing heavily to facilitate future growth. The company has 1,200 new hotel rooms in the pipeline, and has a variety of hotels across The Emerald Isle and the UK due to be opened through the course of 2018.

More specifically, Dalata has its eyes on creating a much larger footprint in Britain, as well as opportunities to buy the freeholds of some of its sites in Ireland to avoid unfavourable rent reviews later down the line. The hotelier this month bought the freehold of certain elements of the Clayton Hotel Cardiff Lane and Clarion Hotel Liffey Valley sites in Dublin for €62.5m.

Get your head down

Dalata has seen earnings detonate in recent years and, if broker forecasts are to believed, investors can expect the bottom line to keep on surging.

A 70% earnings advance is chalked in for 2017, resulting in a P/E ratio of 15.9 times. This figure nudges marginally above the widely-regarded value benchmark of 15 times but is great value given the prospect of further, and sustained, profits growth (an extra 14% rise is expected for 2018 alone).

While Dalata has seen its share price continue its heady ascent (indeed, the hotelier hit another record peak of 450p per share just today), I expect the stock to keep moving higher as earnings steadily expand.

Pumping powerhouse

The City is also in agreement that Spirax-Sarco Engineering (LSE: SPX) should deliver solid earnings expansion in the years ahead. A 17% advance is predicted for 2017, and is expected to be followed with an 8% rise in 2018.

The steam pump play advised this month that an “improving economic background” had helped organic sales in the first four months of 2017 rise above the same period a year ago. And more specifically, Spirax-Sarco has seen sales at its Steam Specialties division improve across all territories, particularly in the hot growth markets of Asia as Chinese and Korean demand takes off.

And excitingly for growth hunters, Spirax-Sarco noted that it intends to “prioritise investments for growth over further margin expansion.” The company sucked up German boiler system specialist Gestra earlier this month for £160m.

I reckon Spirax-Sarco remains a terrific engineering pick irrespective of its high forward P/E ratio of 26.1 times.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »